Judith I Tsui1, Mary A Akosile2, Gwen T Lapham2, Denise M Boudreau2, Eric A Johnson2, Jennifer F Bobb2, Ingrid A Binswanger3, Bobbi Jo H Yarborough4, Joseph E Glass2, Rebecca C Rossom5, Mark T Murphy6, Chinazo O Cunningham7, Julia H Arnsten7, Manu Thakral8, Andrew J Saxon9, Joseph O Merrill1, Jeffrey H Samet10, Gavin B Bart11, Cynthia I Campbell12, Amy M Loree13, Angela Silva6, Angela L Stotts14, Brian Ahmedani13, Jordan M Braciszewski13,15, Rulin C Hechter16, Thomas F Northrup14, Viviana E Horigian17, Katharine A Bradley18. 1. University of Washington/Harborview Medical Center, Seattle, USA. 2. Kaiser Permanente Washington Health Research Institute, 1730 Minor Avenue, STE 1600, Seattle, WA, 98101 (206) 948-1933, USA. 3. Kaiser Permanente Colorado, Colorado Permanente Medical Group, and the University of Colorado School of Medicine, Aurora, USA. 4. Kaiser Permanente Northwest Center for Health Research, Portland, USA. 5. HealthPartners Institute, University of Minnesota, Bloomington, USA. 6. MultiCare Institute for Research and Innovation, MultiCare Health System WA, Seattle, USA. 7. Albert Einstein College of Medicine, Montefiore Medical Center, New York City, USA. 8. College of Nursing and Health Sciences, University of Massachusetts Boston, Boston, USA. 9. Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Health Care System/University of Washington School of Medicine, Seattle, USA. 10. Boston University/Boston Medical Center, Boston, USA. 11. Hennepin Healthcare, University of Minnesota, Minneapolis, USA. 12. Division of Research, Kaiser Permanente Northern California, Oakland, USA. 13. Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, USA. 14. Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Houston, USA. 15. Department of Psychiatry, Henry Ford Health System, Detroit, USA. 16. Department of Research and Evaluation, Kaiser Permanente Southern California, Oakland, USA. 17. Department of Public Health Sciences, Miller School of Medicine, University of Miami, Florida, USA. 18. Kaiser Permanente Washington Health Research Institute, 1730 Minor Avenue, STE 1600, Seattle, WA, 98101 (206) 948-1933, USA. katharine.a.bradley@kp.org.
Abstract
BACKGROUND: Hepatitis C and HIV are associated with opioid use disorders (OUD) and injection drug use. Medications for OUD can prevent the spread of HCV and HIV. OBJECTIVE: To describe the prevalence of documented OUD, as well as receipt of office-based medication treatment, among primary care patients with HCV or HIV. DESIGN: Retrospective observational cohort study using electronic health record and insurance data. PARTICIPANTS: Adults ≥ 18 years with ≥ 2 visits to primary care during the study (2014-2016) at 6 healthcare systems across five states (CO, CA, OR, WA, and MN). MAIN MEASURES: The primary outcome was the diagnosis of OUD; the secondary outcome was OUD treatment with buprenorphine or oral/injectable naltrexone. Prevalence of OUD and OUD treatment was calculated across four groups: HCV only; HIV only; HCV and HIV; and neither HCV nor HIV. In addition, adjusted odds ratios (AOR) of OUD treatment associated with HCV and HIV (separately) were estimated, adjusting for age, gender, race/ethnicity, and site. KEY RESULTS: The sample included 1,368,604 persons, of whom 10,042 had HCV, 5821 HIV, and 422 both. The prevalence of diagnosed OUD varied across groups: 11.9% (95% CI: 11.3%, 12.5%) for those with HCV; 1.6% (1.3%, 2.0%) for those with HIV; 8.8% (6.2%, 11.9%) for those with both; and 0.92% (0.91%, 0.94%) among those with neither. Among those with diagnosed OUD, the prevalence of OUD medication treatment was 20.9%, 16.0%, 10.8%, and 22.3%, for those with HCV, HIV, both, and neither, respectively. HCV was not associated with OUD treatment (AOR = 1.03; 0.88, 1.21), whereas patients with HIV had a lower probability of OUD treatment (AOR = 0.43; 0.26, 0.72). CONCLUSIONS: Among patients receiving primary care, those diagnosed with HCV and HIV were more likely to have documented OUD than those without. Patients with HIV were less likely to have documented medication treatment for OUD.
BACKGROUND: Hepatitis C and HIV are associated with opioid use disorders (OUD) and injection drug use. Medications for OUD can prevent the spread of HCV and HIV. OBJECTIVE: To describe the prevalence of documented OUD, as well as receipt of office-based medication treatment, among primary care patients with HCV or HIV. DESIGN: Retrospective observational cohort study using electronic health record and insurance data. PARTICIPANTS: Adults ≥ 18 years with ≥ 2 visits to primary care during the study (2014-2016) at 6 healthcare systems across five states (CO, CA, OR, WA, and MN). MAIN MEASURES: The primary outcome was the diagnosis of OUD; the secondary outcome was OUD treatment with buprenorphine or oral/injectable naltrexone. Prevalence of OUD and OUD treatment was calculated across four groups: HCV only; HIV only; HCV and HIV; and neither HCV nor HIV. In addition, adjusted odds ratios (AOR) of OUD treatment associated with HCV and HIV (separately) were estimated, adjusting for age, gender, race/ethnicity, and site. KEY RESULTS: The sample included 1,368,604 persons, of whom 10,042 had HCV, 5821 HIV, and 422 both. The prevalence of diagnosed OUD varied across groups: 11.9% (95% CI: 11.3%, 12.5%) for those with HCV; 1.6% (1.3%, 2.0%) for those with HIV; 8.8% (6.2%, 11.9%) for those with both; and 0.92% (0.91%, 0.94%) among those with neither. Among those with diagnosed OUD, the prevalence of OUD medication treatment was 20.9%, 16.0%, 10.8%, and 22.3%, for those with HCV, HIV, both, and neither, respectively. HCV was not associated with OUD treatment (AOR = 1.03; 0.88, 1.21), whereas patients with HIV had a lower probability of OUD treatment (AOR = 0.43; 0.26, 0.72). CONCLUSIONS: Among patients receiving primary care, those diagnosed with HCV and HIV were more likely to have documented OUD than those without. Patients with HIV were less likely to have documented medication treatment for OUD.
Entities:
Keywords:
HIV; buprenorphine; hepatitis C; naltrexone; opioid use disorders
Authors: Jeanette M Tetrault; Janet P Tate; E Jennifer Edelman; Adam J Gordon; Vincent Lo Re; Joseph K Lim; David Rimland; Joseph Goulet; Stephen Crystal; Julie R Gaither; Cynthia L Gibert; Maria C Rodriguez-Barradas; Lynn E Fiellin; Kendall Bryant; Amy C Justice; David A Fiellin Journal: J Subst Abuse Treat Date: 2016-06-06
Authors: Bryan Hartzler; Julia C Dombrowski; Heidi M Crane; Joseph J Eron; Elvin H Geng; W Christopher Mathews; Kenneth H Mayer; Richard D Moore; Michael J Mugavero; Sonia Napravnik; Benigno Rodriguez; Dennis M Donovan Journal: AIDS Behav Date: 2017-04
Authors: Cindy Parks Thomas; Grant A Ritter; Alex H S Harris; Deborah W Garnick; Kenneth I Freedman; Barbara Herbert Journal: J Addict Med Date: 2018 Jul/Aug Impact factor: 3.702
Authors: Jennifer S Potter; Elise N Marino; Maureen P Hillhouse; Suzanne Nielsen; Katharina Wiest; Catherine P Canamar; Judith A Martin; Alfonso Ang; Rachael Baker; Andrew J Saxon; Walter Ling Journal: J Stud Alcohol Drugs Date: 2013-07 Impact factor: 2.582
Authors: Caitlin Conrad; Heather M Bradley; Dita Broz; Swamy Buddha; Erika L Chapman; Romeo R Galang; Daniel Hillman; John Hon; Karen W Hoover; Monita R Patel; Andrea Perez; Philip J Peters; Pam Pontones; Jeremy C Roseberry; Michelle Sandoval; Jessica Shields; Jennifer Walthall; Dorothy Waterhouse; Paul J Weidle; Hsiu Wu; Joan M Duwve Journal: MMWR Morb Mortal Wkly Rep Date: 2015-05-01 Impact factor: 17.586
Authors: E Jennifer Edelman; Kirsha S Gordon; Janis Glover; Ian R McNicholl; David A Fiellin; Amy C Justice Journal: Drugs Aging Date: 2013-08 Impact factor: 3.923
Authors: Matthew Hickman; Colin Steer; Kate Tilling; Aaron G Lim; John Marsden; Tim Millar; John Strang; Maggie Telfer; Peter Vickerman; John Macleod Journal: Addiction Date: 2018-04-19 Impact factor: 6.526
Authors: Ryan R Cook; Randy Torralva; Caroline King; Paula J Lum; Hansel Tookes; Canyon Foot; Pamela Vergara-Rodriguez; Allan Rodriguez; Laura Fanucchi; Gregory M Lucas; Elizabeth N Waddell; P Todd Korthuis Journal: Drug Alcohol Depend Date: 2021-09-20 Impact factor: 4.492